Dr. Saltarelli is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13 Acacia Dr
Tiburon, CA 94920Phone+1 224-430-4681
Education & Training
Johns Hopkins University School of MedicineClass of 1986
Certifications & Licensure
CT State Medical License 2003 - 2019
GA State Medical License 1993 - 2019
Publications & Presentations
PubMed
- 17 citationsAdaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.Robert A. Lenz, Yili Pritchett, Scott M. Berry, Daniel A. Llano, Shu Han
Alzheimer Disease and Associated Disorders. 2015-09-07 - 41 citationsA Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHDEarle E. Bain, Weining Z. Robieson, Yili Pritchett, Tushar S. Garimella, Walid Abi-Saab
Neuropsychopharmacology. 2013-02-01 - 13 citationsA randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.Earle E. Bain, George Apostol, R. Bart Sangal, Weining Z. Robieson, Dawnelle L. McNeill
The Journal of Clinical Psychiatry. 2012-06-15
Press Mentions
As Codiak Enters 'Next Phase of Growth,' Jennifer Wheler Steps into CMO Role; Mark Timney Lines up His Second CEO Opportunity After Purdue Pharma ReignMay 14th, 2021- Chutes & Ladders—Gossamer Vet Salter-Cid Dons CSO Mantle at Flagship's New Pioneering Medicines UnitMay 14th, 2021
Bioasis Announces Annual General Meeting ResultsDecember 5th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
